Pharmaceutical Business review

Schering AG sued over contraceptive patent

In response to news of the allegation, Schering released a statement which affirmed the company’s belief that Yaz does not infringe on the patent, and that the launch of the product will continue as planned.

Warner Chilcott is seeking treble damages, costs and a permanent injunction against Schering and its US affiliate, Berlex. The company said that it intends to launch Loestrin 24 Fe in April.

“Loestrin 24 Fe embodies a novel new dosing regimen for oral contraceptives and Warner Chilcott intends to vigorously defend our rights under our patent to oral contraceptive products delivering 24 days of active therapy,” said Roger Boissonneault, CEO of Warner Chilcott’s parent company. “In addition to recovering damages, we will seek to have Yaz removed from the market.”